GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Retained Earnings

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Retained Earnings : HK$-4,436.7 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Sichuan Kelun-Biotech Biopharmaceutical Co's retained earnings for the quarter that ended in Dec. 2023 was HK$-4,436.7 Mil.

Sichuan Kelun-Biotech Biopharmaceutical Co's quarterly retained earnings increased from Dec. 2022 (HK$-3,888.6 Mil) to Jun. 2023 (HK$-3,842.8 Mil) but then declined from Jun. 2023 (HK$-3,842.8 Mil) to Dec. 2023 (HK$-4,436.7 Mil).

Sichuan Kelun-Biotech Biopharmaceutical Co's annual retained earnings declined from Dec. 2021 (HK$-3,509.4 Mil) to Dec. 2022 (HK$-3,888.6 Mil) and declined from Dec. 2022 (HK$-3,888.6 Mil) to Dec. 2023 (HK$-4,436.7 Mil).


Sichuan Kelun-Biotech Biopharmaceutical Co Retained Earnings Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Retained Earnings Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23
Retained Earnings
-3,509.43 -3,888.60 -4,436.71

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
Sep21 Dec21 Jun22 Sep22 Dec22 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial - -3,564.14 -3,888.60 -3,842.79 -4,436.71

Sichuan Kelun-Biotech Biopharmaceutical Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Sichuan Kelun-Biotech Biopharmaceutical Co  (HKSE:06990) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Traded in Other Exchanges
N/A
Address
No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.
Executives
Liu Gexin 2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Cheng Du Ke Lun Jing Chuan Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Wellington Management Group Llp 2102 Investment manager
Merck & Co., Inc. 2201 Interest of corporation controlled by you
Merck Sharp & Dohme Llc 2101 Beneficial owner
Ke Lun Guo Ji Fa Zhan You Xian Gong Si 2101 Beneficial owner
Li Jun 2201 Interest of corporation controlled by you
Zhou Quan 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates L.p. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates Ltd. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund L.p. 2201 Interest of corporation controlled by you
Victory Rhythm Limited 2201 Interest of corporation controlled by you
Wealthy Linkage Limited 2101 Beneficial owner
Ho Chi Sing 2201 Interest of corporation controlled by you

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines